Challenges And Opportunities When Manufacturing High-Concentration Biotech Drugs
Source: Cytiva

Monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), and recombinant proteins are growing increasingly important as therapeutics for a variety of treatments including cancer, diabetes, and autoimmune diseases such as rheumatoid arthritis (RA) and multiple sclerosis (MS).
As the applications continue to expand for these therapeutics, producing these drugs in a format that can be administered to patients subcutaneously presents significant advantages compared to IV infusion.
Explore opportunities to enhance your platform for high-concentration/subcutaneous drug production.
access the Infographic!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.
Subscribe to Life Science Leader
X
Subscribe to Life Science Leader
This website uses cookies to ensure you get the best experience on our website. Learn more